Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 3242301, 9 pages
https://doi.org/10.1155/2017/3242301
Review Article

Clinical Efficacy and Safety of Total Glucosides of Paeony for Primary Sjögren’s Syndrome: A Systematic Review

1Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China
2Graduate School, Hunan University of Traditional Chinese Medicine, Changsha 410007, China
3Chongqing Engineering Technology Research Center of Traditional Chinese Medicine Characteristics on Diagnosis and Treatment, Chongqing 400021, China

Correspondence should be addressed to Yanping Li; moc.361@gnipnayilsqc and Bin Wu; moc.621@nnibuuw

Received 7 December 2016; Revised 3 April 2017; Accepted 9 May 2017; Published 31 May 2017

Academic Editor: Simon Stebbings

Copyright © 2017 Liang Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To evaluate the clinical efficacy and safety of total glucosides of paeony (TGP) for primary Sjögren’s syndrome (pSS). Methods. Eight electronic databases were searched from their inception to July 2016. Clinical randomized controlled trials (RCTs) were included. The study quality was evaluated according to the standard suggested in the Cochrane Handbook. RevMan 5.1 was used for statistical analysis. Results. Seven RCTs involving 443 patients were included. The results showed that TGP combined with an immunosuppressant (IS) showed greater efficacy for improving the saliva flow test of pSS compared to immunosuppressant alone (WMD −6.88, 95% CI −9.02 to −4.74, and ). And the same trend favouring TGP-IS dual combination was found in Schirmer test (WMD 1.63, 95% CI 0.26 to 3.01, and ), ESR (WMD 7.33, 95% CI −10.08 to −4.59, and ), CRP (WMD −6.00, 95% CI −7.17 to −4.83, and ), IgM (WMD = −0.42, 95% CI −0.70 to 0.13, and ), and IgG (WMD −3.22, 95% CI −4.32 to −2.12, and ) analysis. However, TGP did not affect IgA (WMD 0.53, 95% CI −1.34 to −0.29, and ). The adverse events manifested no significant differences between the two groups. Conclusions. The TGP-IS combination is superior to IS alone in the treatment of pSS. However, due to the low quality of included studies, high-quality RCTs are needed to confirm the beneficial effects of TGP.